Ab­b­Vie picks first Alzheimer's, Parkin­son's tar­gets in Mis­sion pact; Amarin files for Vas­cepa OK in Eu­rope

→ Back in 2018, Ab­b­Vie teamed up with pro­tein degra­da­tion ex­perts at Mis­sion Ther­a­peu­tics to fo­cus on deu­biq­ui­ty­lat­ing en­zymes, or DUBs, to tack­le Alzheimer’s and Parkin­son’s dis­ease. And to­day, the pact has reached its first mile­stone — with Ab­b­Vie choos­ing the pan­el of DUBs that will be pro­gressed for fur­ther char­ac­ter­i­za­tion and screen­ing ac­tiv­i­ties.

→ Af­ter emerg­ing from an ex­pert pan­el re­view last month with a unan­i­mous en­dorse­ment for their fish oil-based heart drug Vas­cepa — bod­ing well for their up­com­ing FDA re­view — Amarin has filed the drug for re­view by the EMA. The drug is al­ready ap­proved in the US for the treat­ment of el­e­vat­ed triglyc­erides, but the com­pa­ny is gun­ning to ex­pand the la­bel to in­clude the re­duc­tion of the in­ci­dence of heart at­tack and stroke in high-risk pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER